Optimizing treatment of CML in the first-line setting and beyond: Insights from EHA 2024 and ESH-iCMLf 2024

touchPODCAST

Contenuto fornito da touchpodcast. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da touchpodcast o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.

5M ago 52:36

MP3•Pagina principale dell'episodio

touchCONGRESS for touchONCOLOGY

Listen to Prof. Gianantonio Rosti, an expert in CML, as he reviews key data presented at the 2024 EHA Hybrid congress and the ESH-iCMLf 26th Annual John Goldman Conference, on tyrosine kinase inhibitors (TKIs) for treating chronic myeloid leukaemia (CML) in the first-and later-line settings. Prof. Rosti is then joined by fellow experts, Prof. Susanne Saussele and Dr Carla Boquimpani, to consider the implications of these data for current and future clinical practice.

Overview

Data reviews with Prof. Rosti
Expert panel discussions with Prof. Susanne Saussele and Dr Carla Boquimpani on the themes below

Clinical themes

Approved and emerging TKIs for CML in the first-line setting
Approved and emerging TKIs for CML in the second- and later-line settings
Potential impact of emerging data on current and future clinical practice

The internationally renowned multiple myeloma expert faculty

Prof. Gianantonio Rosti: Meldola, Italy
Prof. Susanne Saussele: Mannheim, Germany
Dr Carla Boquimpani: Rio de Janeiro, Brazil

This touchPODCAST is for HCPs globally with the exclusion of the USA, the UK and Japan.

This activity is funded by an independent medical education grant from Novartis. This activity is provided by touchIME.

For further information visit our website: TBC

102 episodi

#Science #TouchPODCAST